Intepirdine failed to produce statistically significant improvements compared with placebo in the 24-week HEADWAY trial at either 30mg or 70mg doses in patients with dementia with Lewy bodies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback